JP2018508215A5 - - Google Patents

Download PDF

Info

Publication number
JP2018508215A5
JP2018508215A5 JP2017546104A JP2017546104A JP2018508215A5 JP 2018508215 A5 JP2018508215 A5 JP 2018508215A5 JP 2017546104 A JP2017546104 A JP 2017546104A JP 2017546104 A JP2017546104 A JP 2017546104A JP 2018508215 A5 JP2018508215 A5 JP 2018508215A5
Authority
JP
Japan
Prior art keywords
cell
car
domain
item
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017546104A
Other languages
English (en)
Japanese (ja)
Other versions
JP6574848B2 (ja
JP2018508215A (ja
Filing date
Publication date
Priority claimed from GB201503742A external-priority patent/GB201503742D0/en
Application filed filed Critical
Publication of JP2018508215A publication Critical patent/JP2018508215A/ja
Publication of JP2018508215A5 publication Critical patent/JP2018508215A5/ja
Application granted granted Critical
Publication of JP6574848B2 publication Critical patent/JP6574848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017546104A 2015-03-05 2016-03-04 Cd19結合ドメインを含むキメラ抗原レセプター(car) Active JP6574848B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201503742A GB201503742D0 (en) 2015-03-05 2015-03-05 Chimeric antigen receptor
GB1503742.7 2015-03-05
PCT/GB2016/050574 WO2016139487A1 (en) 2015-03-05 2016-03-04 Chimeric antigen receptor (car) comprising a cd19-binding domain

Publications (3)

Publication Number Publication Date
JP2018508215A JP2018508215A (ja) 2018-03-29
JP2018508215A5 true JP2018508215A5 (https=) 2019-03-07
JP6574848B2 JP6574848B2 (ja) 2019-09-11

Family

ID=52998440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017546104A Active JP6574848B2 (ja) 2015-03-05 2016-03-04 Cd19結合ドメインを含むキメラ抗原レセプター(car)

Country Status (16)

Country Link
US (3) US10457730B2 (https=)
EP (1) EP3265490B1 (https=)
JP (1) JP6574848B2 (https=)
CN (1) CN107406517B (https=)
AU (1) AU2016227498B2 (https=)
CA (1) CA2978381C (https=)
DK (1) DK3265490T3 (https=)
ES (1) ES2732067T3 (https=)
FR (1) FR25C1040I1 (https=)
GB (1) GB201503742D0 (https=)
HU (2) HUE044298T2 (https=)
NL (1) NL301348I2 (https=)
PL (1) PL3265490T3 (https=)
PT (1) PT3265490T (https=)
TR (1) TR201909647T4 (https=)
WO (1) WO2016139487A1 (https=)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2945320A1 (en) 2014-04-10 2015-10-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Drug regulated transgene expression
AU2015259877B2 (en) 2014-05-15 2021-02-25 National University Of Singapore Modified natural killer cells and uses thereof
KR102376244B1 (ko) 2014-12-24 2022-03-21 오토러스 리미티드 세포
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
WO2017027291A1 (en) 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
US9681109B2 (en) * 2015-08-20 2017-06-13 Qualcomm Incorporated Systems and methods for configurable demodulation
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技(香港)有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
KR102660336B1 (ko) * 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN107098981B (zh) * 2017-06-29 2020-05-01 青岛麦迪赛斯医疗技术有限公司 一种靶向cd19的嵌合抗原受体修饰的t淋巴细胞
WO2019025800A1 (en) * 2017-08-02 2019-02-07 Autolus Limited CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE
KR102136063B1 (ko) * 2017-12-06 2020-07-22 앱클론(주) 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항체 수용체 및 이의 용도
CN107903326B (zh) * 2018-01-02 2020-06-30 广东省人民医院(广东省医学科学院) 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
WO2019154313A1 (zh) * 2018-02-11 2019-08-15 江苏恒瑞医药股份有限公司 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
CN116836297A (zh) * 2018-04-12 2023-10-03 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
AU2019269118B2 (en) 2018-05-15 2025-02-27 Autolus Limited Chimeric antigen receptor
GB201807870D0 (en) 2018-05-15 2018-06-27 Autolus Ltd A CD79-specific chimeric antigen receptor
CN108794642A (zh) * 2018-07-05 2018-11-13 宁波安诺柏德生物医药科技有限公司 一种嵌合抗原细胞受体及其应用
CN110819678A (zh) * 2018-08-07 2020-02-21 上海恒润达生生物科技有限公司 一种评估cart细胞有效性的方法
CN110850068B (zh) * 2018-08-21 2023-08-15 上海恒润达生生物科技股份有限公司 一种嵌合抗原受体亲和力检测方法
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
PL3856775T3 (pl) * 2018-09-27 2025-06-09 Autolus Limited Chimeryczny receptor antygenowy
GB201816522D0 (en) 2018-10-10 2018-11-28 Autolus Ltd Methods and reagents for analysing nucleic acids from single cells
WO2020092736A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US12264189B2 (en) 2018-10-31 2025-04-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
SG11202104524YA (en) 2018-11-01 2021-05-28 Gracell Biotechnologies Shanghai Co Ltd Compositions and methods for t cell engineering
CN109468282B (zh) * 2018-11-22 2019-06-18 青岛协和华美医学诊断技术有限公司 一种靶向cd19的嵌合抗原受体t细胞的制备方法及应用
US12590148B2 (en) 2018-11-26 2026-03-31 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
CN109734813B (zh) * 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
JP6821230B2 (ja) * 2019-02-04 2021-01-27 国立大学法人愛媛大学 CARライブラリおよびscFvの製造方法
US12419913B2 (en) 2019-02-08 2025-09-23 Dna Twopointo, Inc. Modification of CAR-T cells
AU2020221821A1 (en) 2019-02-13 2021-08-26 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
AU2020232691B2 (en) 2019-03-05 2023-06-29 Nkarta, Inc. CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
GB201903237D0 (en) 2019-03-08 2019-04-24 Autolus Ltd Method
WO2020183131A1 (en) 2019-03-08 2020-09-17 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
JP7629414B2 (ja) * 2019-06-04 2025-02-13 ンカルタ・インコーポレイテッド 免疫療法のための操作されたナチュラルキラー細胞と操作されたt細胞の組み合わせ
JP2022539248A (ja) 2019-07-02 2022-09-07 フレッド ハッチンソン キャンサー リサーチ センター 組換えad35ベクター及び関連遺伝子治療改善
WO2021009694A1 (en) * 2019-07-17 2021-01-21 National University Of Singapore Functional binders synthesized and secreted by immune cells
EP4021485A1 (en) 2019-08-28 2022-07-06 King's College London B cell targeted parallel car (pcar) therapeutic agents
EP4065605A4 (en) 2019-11-26 2023-07-12 Ramot at Tel-Aviv University Ltd. Antibodies to carbohydrate antigens
WO2021146147A1 (en) * 2020-01-13 2021-07-22 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and compositions for treating cancer with immune cells
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技(香港)有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
GB202005216D0 (en) 2020-04-08 2020-05-20 Autolus Ltd Cell
US20230348854A1 (en) * 2020-05-08 2023-11-02 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Chimeric antigen receptors (cars) targeting natural killer cells
US20220031751A1 (en) 2020-08-03 2022-02-03 Kyverna Therapeutics, Inc. Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same
WO2022072515A1 (en) * 2020-09-29 2022-04-07 Washington University Methods to determine risk of neurotoxicity
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
EP4271817A2 (en) 2020-12-30 2023-11-08 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022165419A1 (en) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Methods for increasing t-cell function
WO2022214089A1 (zh) * 2021-04-08 2022-10-13 克莱格医学有限公司 细胞免疫治疗的应用
JP2025516531A (ja) 2022-05-11 2025-05-30 オートラス リミテッド 高リスクまたは再発性小児急性リンパ芽球性白血病のcd19/22 car t細胞処置
CN117088975B (zh) * 2022-05-11 2024-06-25 东莞市朋志生物科技有限公司 抗白蛋白抗体、检测白蛋白的试剂和试剂盒
CN116253794B (zh) * 2022-08-19 2025-04-04 首都医科大学宣武医院 一种用于car-t细胞调控的抗体及其应用
CA3278900A1 (en) 2023-03-31 2024-10-03 AbelZeta Inc. BISPECIFIC CHIMERIC ANTIGENIC RECEPTORS TARGETING CD20 AND BCMA
WO2024246526A1 (en) 2023-05-30 2024-12-05 Autolus Limited Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia
WO2025008642A1 (en) 2023-07-05 2025-01-09 Autolus Limited Method
CN119350497A (zh) * 2023-07-24 2025-01-24 星尘生物科技(上海)有限公司 人源化抗cd19单链可变区片段及其用途
GB202316184D0 (en) 2023-10-23 2023-12-06 Autolus Ltd Method
WO2025088308A1 (en) 2023-10-23 2025-05-01 Autolus Limited Products and methods for treating autoimmune diseases
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners
GB202403564D0 (en) 2024-03-12 2024-04-24 Autolus Ltd Method
WO2025215360A1 (en) 2024-04-09 2025-10-16 Autolus Limited Method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
WO2013126712A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
PL3546572T3 (pl) * 2013-05-13 2024-07-22 Cellectis Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania
KR102376244B1 (ko) 2014-12-24 2022-03-21 오토러스 리미티드 세포
GB201503742D0 (en) * 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor

Similar Documents

Publication Publication Date Title
JP2018508215A5 (https=)
KR102483822B1 (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
JP2017508466A5 (https=)
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
CN112638947B (zh) 用于治疗实体瘤的嵌合抗原受体细胞
CN112390892B (zh) 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
JP2018527919A5 (https=)
JP2019532625A5 (https=)
JP2017500869A5 (https=)
RU2017121892A (ru) Клетка
JP2015527070A5 (https=)
JP2016520074A5 (https=)
JP2018528776A5 (https=)
JP2019530431A5 (https=)
JP2019535262A5 (https=)
KR20200041377A (ko) Strep-tag 특이적 결합 단백질 및 그 용도
CN118843693A (zh) 靶向bcma的嵌合抗原受体及其应用
JP2022530541A (ja) Bcmaを標的とするcar t細胞及びその使用
WO2023193660A1 (zh) 增强型嵌合抗原受体及其应用
WO2024017362A1 (zh) 靶向gprc5d和/或bcma的嵌合抗原受体及其应用
US20250236864A1 (en) CAR LIBRARY AND scFv MANUFACTURING METHOD
EP4007777B1 (en) Car t-cells against bcma for the treatment of multiple myeloma
JP2020509745A5 (https=)
JPWO2020144697A5 (https=)
WO2025082340A1 (zh) 一种靶向δ样配体3的CAR及应用